$GSK Company News Mylan in second round bid for Glaxo

New Post Public Reply Private Reply Replies (0) Message Board

Aug 23, 2014 at 12:21 PM

$GSK Company News

Mylan in second round bid for Glaxo portfolio: WSJ 2:39 p.m. Aug. 20, 2014 - MarketWatch.com
Glaxo chief faces increasing pressure: WSJ 6:29 p.m. Aug. 11, 2014 - MarketWatch.com
Super-Moon illusion or buy the dips on this stock market? 7:52 a.m. Aug. 11, 2014 - Barbara Kollmeyer
China’s anti-corruption drive: Is it reform in disguise? 1:26 a.m. Aug. 11, 2014 - Craig Stephen
Hungry for yield? Gobble up European stocks, says Goldman 10:43 a.m. Aug. 5, 2014 - Carla Mozee
FTSE 100 slumps for third day as miners, banks slump 12:12 p.m. Aug. 1, 2014 - Sara Sjolin
FTSE 100 erases gain after soft U.S. home sales data 12:07 p.m. July 28, 2014 - Sara Sjolin
Biogen rallies on earnings; Juniper slumps 10% 1:25 p.m. July 23, 2014 - Sue Chang
Glaxo slides in London after earnings warning 12:02 p.m. July 23, 2014 - Carla Mozee
GlaxoSmithKline lowers full-year profit outlook 7:48 a.m. July 23, 2014 - MarketWatch.com
U.K. growth data to reignite BOE rate chatter 5:08 a.m. July 22, 2014 - blogs.marketwatch.com
Emerging markets lift Novartis profit by 1.6% 1:39 a.m. July 17, 2014 - MarketWatch.com
Novartis lays out plan to overhaul business 3:14 a.m. June 18, 2014 - MarketWatch.com
GlaxoSmithKline reaches $105 million settlement with 44 states 3:19 p.m. June 4, 2014 - Russ Britt
Merck, Sanofi, Glaxo explore shedding older drugs 5:43 p.m. June 3, 2014 - MarketWatch.com
GlaxoSmithKline says U.K. fraud office is probing its commercial work 4:07 p.m. May 27, 2014 - Russ Britt
GlaxoSmithKline says U.K. fraud office probing firm 3:27 p.m. May 27, 2014 - Russ Britt
Vodafone pulls FTSE 100 from 14-year high 12:18 p.m. May 15, 2014 - Sara Sjolin
Glaxo's ex-China chief accused of bribery 1:20 a.m. May 14, 2014 - MarketWatch.com
Glaxo profit slides by almost a third 10:07 a.m. April 30, 2014 - MarketWatch.com

FDA approves single-pill regimen HIV med 3:32 p.m. Aug. 22, 2014 - Seeking Alpha
GlaxoSmithKline's (GSK) Arnuity Ellipta Approved by FDA - Analyst Blog 5:05 p.m. Aug. 21, 2014 - Zacks.com
3 Dividend Kings From The U.K. I Love To Buy 3:01 p.m. Aug. 21, 2014 - GuruFocus.com
Theravance Biopharma: Neglected Spinoff Targeting A Huge Underserved Market 9:32 a.m. Aug. 21, 2014 - Seeking Alpha
Novartis to Invest $35M in Gamida Cell for 15% Equity - Analyst Blog 6:13 p.m. Aug. 20, 2014 - Zacks.com
GSK expands fluticasone furoate label into asthma 3:49 p.m. Aug. 20, 2014 - Seeking Alpha
GlaxoSmithKline: The Bad Isn't All That Bad 3:39 p.m. Aug. 20, 2014 - Seeking Alpha
Why Mylan (MYL) Stock Is Advancing Today 3:01 p.m. Aug. 20, 2014 - TheStreet.com
UPDATE: GlaxoSmithKline Receives FDA Approval For Arnuity Ellipta In US For Treatment Of Asthma 2:36 p.m. Aug. 20, 2014 - benzinga.com
Hottest Healthcare Stocks Now – THOR GSK ESRX CNC 1:45 p.m. Aug. 20, 2014 - InvestorPlace.com
Eurozone Recovery Stalls in Q2: 3 Stocks to Sell Now - Analyst Blog 9:59 a.m. Aug. 20, 2014 - Zacks.com
Pernix acquires U.S. rights to Treximet 9:03 a.m. Aug. 20, 2014 - Seeking Alpha
Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win 6:01 a.m. Aug. 20, 2014 - TheStreet.com
GlaxoSmithKline: To Buy Or Not To Buy? 12:27 p.m. Aug. 19, 2014 - Seeking Alpha
Kindred 30.33% Upside Paced Healthcare August Dividend Dogs 9:18 p.m. Aug. 18, 2014 - Seeking Alpha
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China 2:11 p.m. Aug. 18, 2014 - TheStreet.com
Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG 10:54 a.m. Aug. 18, 2014 - GuruFocus.com
Why GlaxoSmithKline Is A Tempting Buy 5:10 p.m. Aug. 14, 2014 - Seeking Alpha
Major Portfolio Changes for Warren Buffett and Berkshire Hathaway 4:40 p.m. Aug. 14, 2014 - 247WallSt.com
Ebola vaccine trials are a top priority for medical authorities 1:20 p.m. Aug. 14, 2014 - Seeking Alpha

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection 3:46 p.m. Aug. 22, 2014 - PR Newswire - PRF
Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 11:00 a.m. Aug. 21, 2014 - PR Newswire - PRF
Pharma Stocks Review -- Eli Lilly, Zogenix, GlaxoSmithKline, Novo Nordisk, and Valeant Pharma Intl. 9:20 a.m. Aug. 21, 2014 - PR Newswire - PRF
GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the US for the treatment of asthma 3:33 p.m. Aug. 20, 2014 - PR Newswire - PRF
Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance. 8:02 a.m. Aug. 20, 2014 - BusinessWire - BZX
POZEN Announces U.S. Rights For TREXIMET® Have Been Acquired by Pernix Therapeutics 8:00 a.m. Aug. 20, 2014 - BusinessWire - BZX
North American Pharma-Biotech Sector to Wrap Up Construction on 157 Projects Worth $1.3 Billion in Third-Quarter 2014, an Industrial Info News Alert 6:15 a.m. Aug. 20, 2014 - Marketwire
Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 1:19 p.m. Aug. 19, 2014 - PR Newswire - PRF
Sanford-Burnham Appoints Perry Nisen as Chief Executive Officer 1:00 p.m. Aug. 19, 2014 - Marketwire
Drug Approvals & Updates, Licensing Agreements, and Upcoming Conferences - Research Reports on Tekmira, MannKind, Eli Lilly, GSK and Cigna 8:30 a.m. Aug. 14, 2014 - PR Newswire - PRF
Inotek Pharmaceuticals Names David P. Southwell as President and Chief Executive Officer 9:01 a.m. Aug. 13, 2014 - BusinessWire - BZX
Potential Payoffs Spur Big Board Biotech Action 3:03 p.m. Aug. 12, 2014 - ACCESSWIRE
Thrasos Appoints Gaétan Gravel andJoseph Zakrzewski to Board of Directors 9:01 a.m. Aug. 12, 2014 - BusinessWire - BZX
Spasticity Global Clinical Trials Review, H2, 2014 4:42 p.m. Aug. 11, 2014 - PR Newswire - PRF
Spastic Cerebral Palsy Global Clinical Trials Review, H2, 2014 4:39 p.m. Aug. 11, 2014 - PR Newswire - PRF
Sears Holdings Names Alasdair James As Kmart's President And Chief Member Officer 2:47 p.m. Aug. 11, 2014 - PR Newswire - PRF
Sponsor And CRO Finalists Announced For Annual Society For Clinical Research Sites Eagle Award 12:08 p.m. Aug. 11, 2014 - PR Newswire - PRF
Dynavax Reports Second Quarter 2014 Financial Results and Safety and Pharmacodynamic Results for Asthma and Lupus Drug Candidates 6:01 a.m. Aug. 7, 2014 - Marketwire
New Joint Ventures, Course Launches, Study Results, Earnings Performance, and Approvals - Research Reports on Johnson Controls, Intuitive Surgical, GlaxoSmithKline, Community Health and Vertex 8:50 a.m. Aug. 6, 2014 - PR Newswire - PRF
GSK's COPD.com Relaunch Promotes Understanding and Dialogue about COPD 9:00 a.m. Aug. 5, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

The Chemical Industry and EPA: A Broken System?

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Anecdotes by Artists Brings Raw Scent Stories to Sephora

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

FutureVault's AI Agents: Transforming Financial Workflows

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

HTX's Strategic Moves in Pakistan: A Crypto Frontier

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Davos Healthcare Aims to Revolutionize Hospital Ratings

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...